Conformis, Inc. to Release Second Quarter 2021 Financial Results on August 4, 2021

Rhea-AI Summary

Conformis, Inc. (NASDAQ: CFMS) will announce its Q2 2021 financial results on August 4, 2021, after market close. A conference call, led by CEO Mark Augusti and CFO Bob Howe, will take place at 4:30 p.m. Eastern Time on the same day. Investors can access the details via webcast or telephone, with a conference ID of 7040896. The company's innovative iFit Image-to-Implant technology offers customized joint replacements, aiming for better patient outcomes compared to conventional implants. More information will be available on their Investor Relations website.

Positive

• Conformis' iFit technology is recognized for superior clinical outcomes and patient satisfaction in joint replacements.
• The company has a strong pipeline of personalized joint replacement products.

Negative

• None.

BILLERICA, Mass., July 01, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS) announced today that it will release its financial results for the second quarter ended June 30, 2021 after the market closes on August 4, 2021 at approximately 4:00 p.m. Eastern Time.

Mark Augusti, CEO, and Bob Howe, CFO, will host a webcast and conference call also on Wednesday, August 4, 2021, at 4:30 p.m. Eastern Time to discuss the financial results and to provide a business update.

The webcast will be live at:   https://edge.media-server.com/mmc/p/djinyqx6.

To attend by telephone, please use the information below for dial-in access.

• When prompted on dial-in, please utilize conference ID: 7040896.
• Participant conference numbers (877) 809-6331 (U.S./Canada) and (615) 247-0224 (International).
• Please dial in at least 10 minutes before the call to ensure timely participation.
  

Please visit the Investor Relations website at ir.conformis.com on August 4, 2021 to view the earnings release prior to the webcast and conference call.

The online archive of the webcast will be available on the company’s website at ir.conformis.com for 30 days.

About Conformis, Inc.

Conformis is a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture, and sell joint replacement implants and instruments that are individually sized and shaped, which we refer to as personalized, individualized, or sometimes as customized, to fit each patient's unique anatomy. Conformis offers a broad line of sterile, personalized knee and hip implants and single-use instruments delivered to hospitals and ambulatory surgical centers. In clinical studies, the Conformis iTotal CR knee replacement system demonstrated superior clinical outcomes, including better function and greater patient satisfaction, compared to traditional, off-the-shelf implants. Conformis owns or exclusively in-licenses issued patents and pending patent applications that cover personalized implants and patient-specific instrumentation for all major joints.

For more information, visit www.conformis.com. To receive future releases in e-mail alerts, sign up at http://ir.conformis.com/.

 

FAQ

When will Conformis release its Q2 2021 financial results?

Conformis will release its financial results for Q2 2021 on August 4, 2021, after market close.

What time is the Conformis conference call scheduled for?

The conference call will be held on August 4, 2021, at 4:30 p.m. Eastern Time.

How can I access Conformis' earnings call?

You can access the earnings call via webcast or telephone using the conference ID 7040896.

What technology does Conformis use for joint replacements?

Conformis utilizes its proprietary iFit Image-to-Implant technology platform for customized joint replacement implants.

Where can I find more information about Conformis?

More information can be found on Conformis' Investor Relations website.